Considering the Biden Administration’s Regulation of “Ghost Guns” by the ATF Under the Gun Control Act of 1968.

*Ellie Roser

I. Introduction

Privately made firearms created from “firearm parts kits, standalone frame or receiver parts, and easy to complete frames or receivers,” also known as ghost guns, pose a unique issue in firearm regulation.[1] Purchasers typically buy ghost guns in kits or create the individual parts using 3-D printers, and can then easily assemble the parts into a useable gun.[2] Ghost guns bypass federal requirements imposed on other gun manufacturers because ghost guns are not fully assembled upon purchase, and they can be purchased without a background check or serial number.[3] The Gun Control Act of 1968 imposes requirements on gun manufacturers including: obtaining a license, keeping records of sales, conducting background checks, and issuing a serial number with each gun sold.[4] Because ghost guns do not have serial numbers, law enforcement agencies cannot track a gun to its purchaser, presenting a difficult roadblock to identifying their origin.[5] Law enforcement agencies  reported “a ten-fold increase from 2016” of ghost guns in their criminal investigations.[6]

Continue reading “Considering the Biden Administration’s Regulation of “Ghost Guns” by the ATF Under the Gun Control Act of 1968.”

Call to Stop Criminalizing Youth Behavior Through House Bill 615

*Manna Alexander

Maryland, along with many other states, has a statute that criminalizes “disruptive behavior” in schools.[1] Qualifying behaviors can range from assault to a verbal disagreement with another student, roaming the halls, or anything the school deems “disruptive.”[2] Due to the existing statute’s overly broad nature, legislators, attorneys, and other concerned parties have proposed and rallied behind House Bill 615 in an effort to mitigate the criminalization of youth behaviors in schools.[3]

Continue reading “Call to Stop Criminalizing Youth Behavior Through House Bill 615”

The First Amendment’s Second Look: Echoes of the 1960s Anti-War Movement in Today’s Israel-Palestine Protests

*Elle Johnson

I. Introduction

College campuses noticed a major uptick in student-led protests and demonstrations after the Israel-Palestine conflict escalated in October 2023.[1] In Spring 2024, law enforcement officers arrested thousands of student protesters in Spring 2024,[2] an eerie reminder to many Americans of a similar time in U.S. history: the 1960s Anti-War Movement.[3]

Continue reading “The First Amendment’s Second Look: Echoes of the 1960s Anti-War Movement in Today’s Israel-Palestine Protests”

FTC’s Non-Compete Ban Faces Challenges: Chevron Deference Overturned and District Court Ruling Cast Doubts on Rule’s Validity

*William Cellitto

In 1914, Congress enacted the Federal Trade Commission Act (the Act).[1] The Act established the Federal Trade Commission (the FTC)[2] and vested the FTC with the power to prevent the use of “unfair methods of competition in or affecting commerce, and unfair or deceptive acts or practices in or affecting commerce.”[3] On April 23, 2024, the FTC adopted a Non-Compete Rule (the Rule) that prohibits employers from entering into non-compete agreements with employees and requires them to rescind existing non-compete agreements by the Rule’s compliance date.[4]

Continue reading “FTC’s Non-Compete Ban Faces Challenges: Chevron Deference Overturned and District Court Ruling Cast Doubts on Rule’s Validity”

High Prescription Drug Prices Are Slowly Gaining Attention From the Government. What is Being Done and Is It Enough?

*Billy Cadogan

I. Introduction

The United States began to spend significantly more on prescription drugs per capita compared to the rest of the world in the mid-1990s.[1] The increase in prices and the business practices within the prescription drug industry have gotten so out of hand that the Federal Trade Commission (FTC) filed a lawsuit against the three biggest pharmacy benefit managers (PBMs) for anticompetitive practices and market manipulation, alleging the PBMs steer patients toward more expensive drugs and exclude cheaper alternatives from their formularies.[2] The FTC filed suit against the three largest PBMs on September 20, 2024 for engaging in anticompetitive and unfair rebate practices which have led to artificially inflated prices and limited access to lower-priced alternatives.[3] The suit and FTC investigation have potential to bring transparency and fairness to the prescription drug market.[4]

Continue reading “High Prescription Drug Prices Are Slowly Gaining Attention From the Government. What is Being Done and Is It Enough?”